Estudo de braço único fase 1b | Venetoclax com gilteritinibe para leucemia mieloide aguda recorrente/refratária com mutação de FLT3.
2 Ago, 2022 | 12:52h
Comentário no Twitter
🙌 Venetoclax plus gilteritinib yields modified composite complete response of 75% in FLT3-mutated relapsed/refractory #AcuteMyeloidLeukemia
Read in #JCO ➡️ https://t.co/L7wxJ63qv9 #AML #leusm @Daver_Leukemia @jaltmanmd pic.twitter.com/ksXw1DNMsE
— Journal of Clinical Oncology (@JCO_ASCO) July 29, 2022